Evidence map›Paper›PMID 36975050›Full record

ArticleJMIR formative research2023

Engagement, Retention, and Acceptability in a Digital Health Program for Atopic Dermatitis: Prospective Interventional Study.

Sigrídur Lára Gudmundsdóttir, Tommaso Ballarini, María L Ámundadóttir, Judit Mészáros, Jenna Huld Eysteinsdottir, Ragna H Thorleifsdottir, Sigrídur K Hrafnkelsdóttir, Halla Helgadottir, Saemundur Oddsson, Jonathan I Silverberg

Open access · goldAbstract read
In one paragraph

Article in JMIR formative research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Article
  7. Knowledge assessment tools in atopic dermatitis patient education: a scoping review.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2025
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Sigrídur Lára GudmundsdóttirSidekick Health Digital Therapeutics, Kopavogur, Iceland.ORCID https://orcid.org/0000-0002-6189-5894
Tommaso BallariniSidekick Health Digital Therapeutics, Berlin, Germany.ORCID https://orcid.org/0000-0001-7299-5973
María L ÁmundadóttirSidekick Health Digital Therapeutics, Kopavogur, Iceland.ORCID https://orcid.org/0000-0002-6066-6600
Judit MészárosSidekick Health Digital Therapeutics, Berlin, Germany.ORCID https://orcid.org/0000-0002-8196-9061
Jenna Huld EysteinsdottirHudlaknastodin Dermatology Clinic, Kopavogur, Iceland.ORCID https://orcid.org/0000-0001-6623-8298
Ragna H ThorleifsdottirHudlaknastodin Dermatology Clinic, Kopavogur, Iceland.ORCID https://orcid.org/0009-0006-2899-4619
Sigrídur K HrafnkelsdóttirSidekick Health Digital Therapeutics, Kopavogur, Iceland.ORCID https://orcid.org/0009-0002-3851-5117
Halla HelgadottirSidekick Health Digital Therapeutics, Kopavogur, Iceland.ORCID https://orcid.org/0000-0003-3743-5852
Saemundur OddssonSidekick Health Digital Therapeutics, Kopavogur, Iceland.ORCID https://orcid.org/0000-0001-9427-443X
Jonathan I SilverbergSchool of Medicine and Health Sciences, George Washington University, Washington, DC, United States.ORCID https://orcid.org/0000-0003-3686-7805
University of Iceland · ISGeorge Washington University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with atopic dermatitis can experience chronic eczema with pruritus, skin pain, sleep problems, anxiety, and other problems that reduce their quality of life (QoL). Current treatments aim to improve these symptoms and reduce inflammation, but poor treatment adherence and disease understanding are key concerns in the long-term management of atopic dermatitis. Digital therapeutics can help with these and support patients toward a healthier lifestyle to improve their overall QoL.

objectiveThe aim of the study is to test the feasibility of a digital health program tailored for atopic dermatitis through program engagement, retention, and acceptability.

methodsAdults with atopic dermatitis were recruited in Iceland for a 6-week digital health program delivered through a smartphone app. Key components of the digital program were disease and trigger education; medication reminders; patient-reported outcomes (PROs) on energy levels, stress levels, and quality of sleep (referred to as QoL PROs); atopic dermatitis symptom PROs; guided meditation; and healthy lifestyle coaching. The primary outcome was program feasibility, as assessed by in-app retention and engagement. User satisfaction was assessed by the mHealth (ie, mobile health) App Usability Questionnaire (MAUQ).

resultsA total of 21 patients were recruited (17 female, mean age 31 years), 20 (95%) completed the program. On average, users were active in the app 6.5 days per week and completed 8.2 missions per day. The education content, medication reminders, and PROs had high user engagement and retention; all users who were exposed to the QoL PROs (n=17) interacted with these, and 20/21 (95%) users were continuously engaged with the education missions, medication missions, and symptom PROs. Continued engagement with the step counter and mind missions among exposed users was lower (17/21 and 13/20 participants, respectively). Medication reminder and education task completion remained high over time (at least 18/20, 90%), but weekly interactions declined. All assigned users completed atopic dermatitis symptom PROs on weeks 1-5 and only one did not do so on week 6; the reported number and total severity of atopic dermatitis symptoms reduced during the program. Regarding the QoL PROs, 16/17 (94%) and 14/17 (82%) users interacted with these at least 3 times in the first and last week of the program, respectively, and all reported improvements over time. User satisfaction was high with a total score of 6.2/7.

conclusionsWe found high overall engagement and retention in a targeted digital health program among patients with atopic dermatitis, as well as high compliance with missions relating to medication reminders, patient education, and PROs. Symptom number and severity were reduced, and QoL PROs improved over time. We conclude that a digital health program is feasible and may provide added benefits for patients with atopic dermatitis, including the tracking and improvement of atopic dermatitis symptoms.

Indexed as

atopic dermatitisdermatologydigital therapeuticsDTXeczemaeHealthengagementfeasibilitymedication remindermobile phonepatient-reported outcomesquality of liferetentionsymptom tracking

Identifiers

PMID36975050
PMCPMC10337350
OpenAlexW4361015781

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.